AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34647586 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal changes in PRECISE-DAPT score
Number of subjects: 0
Study 34647602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120mg for ≥ 3 months and < 3 years
Number of subjects: 128
Study 34647773 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine concentration with high device power
Number of subjects: 0
Study 34647773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine concentration with low device power
Number of subjects: 0
Study 34647773 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34647849 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab + chemotherapy
Number of subjects: 0
Study 34647849 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy alone
Number of subjects: 0
Study 34647890 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-QCA-based vessel FFR (vFFR)
Number of subjects: 334
Study 34647890 — intervention group
Group type: COMPARATOR
Intervention: Pressure wire-based FFR (≤0.80)
Number of subjects: 334
Study 34647893 — intervention group
Group type: EXPERIMENTAL
Intervention: MoST-MH
Number of subjects: 52
Study 34647893 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (eUC)
Number of subjects: 52
Study 34647988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib 160 mg once daily
Number of subjects: 114
Study 34648087 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Ra/Re ratio and arterial hypertension duration
Number of subjects: 60
Study 34648087 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GFR measurement
Number of subjects: 60
Study 34648147 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Treatment Convenience Scale (PTCS)
Number of subjects: 794
Study 34649015 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 0
Study 34649106 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 191
Study 34649106 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 191
Study 34649279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (1000 mg IV on days 0 and 14) and prednisone (1 mg/kg/day)
Number of subjects: 38
Study 34649279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab and prednisone
Number of subjects: 38
Study 34649276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg/d for 48 weeks plus prednisone tapered to 60 mg/m2/d from days -14 to 29; prophylactic intrathecal chemotherapy administered monthly.
Number of subjects: 44
Study 34649276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib and prednisone
Number of subjects: 44
Study 34649307 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting 4 (addition of NAFLD-associated variables including presence of NAFLD and laboratory results)
Number of subjects: 1443
Study 34649307 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting 5 (top 11 variables identified from a stepwise variable selection method)
Number of subjects: 1443
Study 34649307 — intervention group
Group type: COMPARATOR
Intervention: Settings 1-3 (conventional risk factors and addition of new risk factors)
Number of subjects: 1443
Study 34649468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic Experiences and Perceptions Scale (PEPS) subscales
Number of subjects: 309
Study 34649468 — intervention group
Group type: EXPERIMENTAL
Intervention: Maslach Burnout Inventory (MBI)
Number of subjects: 309
Study 34649504 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement component 7 (CC7)
Number of subjects: 1853
Study 34649504 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1853
Study 34649522 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient phenogroup (non-adequate sleep and ideal cardiovascular health)
Number of subjects: 307
Study 34649522 — intervention group
Group type: COMPARATOR
Intervention: Concordant phenogroup (adequate sleep and ideal cardiovascular health)
Number of subjects: 307
Study 34649522 — intervention group
Group type: COMPARATOR
Intervention: Uncoupled phenogroup (adequate sleep and non-ideal cardiovascular health)
Number of subjects: 307
Study 34649621 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Blame and Perspective-Taking Intervention (SBPI)
Number of subjects: 24
Study 34649784 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary app-supported tele-counseling intervention (8 weeks duration, weekly dietitian tele-counseling)
Number of subjects: 44
Study 34649784 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary app-supported tele-counseling intervention
Number of subjects: 44
Study 34649873 — intervention group
Group type: EXPERIMENTAL
Intervention: VY-AADC01 (AAV2 gene therapy) delivered via bilateral, intraoperative MRI-guided putaminal infusions.
Number of subjects: 15
Study 34649883 — intervention group
Group type: EXPERIMENTAL
Intervention: CT hypoperfusion-hypodensity mismatch
Number of subjects: 666
Study 34649942 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-targeted PET
Number of subjects: 0
Study 34649942 — intervention group
Group type: COMPARATOR
Intervention: mpMRI
Number of subjects: 0
Study 34649967 — intervention group
Group type: EXPERIMENTAL
Intervention: Miransertib (MK-7075)
Number of subjects: 0
Study 34649967 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34650132 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis-associated pain symptoms (pelvic pain, pain after/during sexual intercourse, painful menstrual periods)
Number of subjects: 27840
Study 34650132 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful periods
Number of subjects: 27840
Study 34650132 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy/irregular bleeding
Number of subjects: 27840
Study 34650132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic pain
Number of subjects: 27840
Study 34650132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood impact due to endometriosis
Number of subjects: 27840
Study 34650392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1200
Study 34650392 — intervention group
Group type: COMPARATOR
Intervention: Control (no lifestyle intervention)
Number of subjects: 1200
Study 34650509 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular recanalization
Number of subjects: 0
Study 34650509 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 0
Study 34650930 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with corticosteroids (5 mg/kg, two to four cycles)
Number of subjects: 123
Study 34650930 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab monotherapy
Number of subjects: 123
Study 34651137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral dextrose infusion (50% dextrose; 0.5 g/mL) at 10 mL per hour for 24 hours
Number of subjects: 58
Study 34651137 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 58
Study 34651222 — intervention group
Group type: EXPERIMENTAL
Intervention: Enerisant hydrochloride (5 mg)
Number of subjects: 2
Study 34651222 — intervention group
Group type: EXPERIMENTAL
Intervention: Enerisant hydrochloride (12.5 mg)
Number of subjects: 2
Study 34651222 — intervention group
Group type: EXPERIMENTAL
Intervention: Enerisant hydrochloride (25 mg)
Number of subjects: 2
Study 34651227 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid nomograms combining RS with IPI
Number of subjects: 152
Study 34651227 — intervention group
Group type: EXPERIMENTAL
Intervention: TMTV-based hybrid nomograms
Number of subjects: 152
Study 34651227 — intervention group
Group type: EXPERIMENTAL
Intervention: MBV-based hybrid nomograms
Number of subjects: 152
Study 34651227 — intervention group
Group type: EXPERIMENTAL
Intervention: TMTV- and MBV-based hybrid nomograms
Number of subjects: 152
Study 34651227 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid nomograms
Number of subjects: 152
Study 34651291 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR4-directed PET/CT
Number of subjects: 26
Study 34652548 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVI SCOUT® reflector (SAVI)
Number of subjects: 25
Study 34652551 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modality image sets: in vivo T2-weighted (T2w)-MRI, 22-min dynamic
Number of subjects: 0
Study 34652768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia residents who died within 6 months (n=240)
Number of subjects: 2688
Study 34652768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia residents
Number of subjects: 2688
Study 34653030 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-connected hearing aids controlled by a prototype app
Number of subjects: 8
Study 34653210 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG) with Hizentra every 7±2 days for 24 weeks
Number of subjects: 15
Study 34653210 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG) with Hizentra
Number of subjects: 15
Study 34653238 — intervention group
Group type: EXPERIMENTAL
Intervention: NNK genetic cluster (58% of cases)
Number of subjects: 303
Study 34653238 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT genetic cluster (32% of cases)
Number of subjects: 303
Study 34653238 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-suppressive SMZL (50% of cases)
Number of subjects: 303
Study 34653238 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-silent SMZL (50% of cases)
Number of subjects: 303
Study 34653242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 20 mg PO twice daily until progression
Number of subjects: 52
Study 34653242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 52
Study 34653252 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinecerfont 100 mg twice daily for 14 days
Number of subjects: 18
Study 34653252 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinecerfont 100 mg once daily at bedtime for 14 days
Number of subjects: 18
Study 34653252 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinecerfont 100 mg once daily in the evening for 14 days
Number of subjects: 18
Study 34653252 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinecerfont 50 mg once daily at bedtime for 14 days
Number of subjects: 18
Study 34653374 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal latent class analysis identified two distinct subphenotypes.
Number of subjects: 1007
Study 34653374 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelling ventilatory ratio and mechanical power parameters.
Number of subjects: 1007
Study 34653525 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 Gy whole-lung LD-RT
Number of subjects: 40
Study 34653525 — intervention group
Group type: COMPARATOR
Intervention: Standard drug treatments without LD-RT
Number of subjects: 40
Study 34653567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem T Slim X2™ with Basal-IQ™ (TTSX2)
Number of subjects: 44
Study 34653567 — intervention group
Group type: COMPARATOR
Intervention: Medtronic Minimed 640G™ with SmartGuard (MM640G)
Number of subjects: 44
Study 34654246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing homes located in rural areas
Number of subjects: 5926
Study 34654246 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy for internal use (PUI)
Number of subjects: 5926
Study 34654246 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a personalized care project
Number of subjects: 5926
Study 34654263 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 3000
Study 34654263 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 3000
Study 34654283 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical recommendations by clinical pharmacists
Number of subjects: 30
Study 34654283 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy recommendations
Number of subjects: 30
Study 34654283 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive algorithm for pharmacotherapeutic evaluation
Number of subjects: 30
Study 34654375 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship characteristics measured with self-report measures and the Partnership Approach Questionnaire.
Number of subjects: 300
Study 34654464 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) plus treatment as usual (TAU)
Number of subjects: 200
Study 34654464 — intervention group
Group type: COMPARATOR
Intervention: Enhanced self-help intervention (self-help guide book, 12-h workshop, 1-h individual vocational guidance) plus TAU
Number of subjects: 200
Study 34654792 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h automated office blood pressure measurement
Number of subjects: 562
Study 34654792 — intervention group
Group type: COMPARATOR
Intervention: Conventional home blood pressure monitoring
Number of subjects: 562
Study 34655331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic graded upper-body exercise in cold (-15°C)
Number of subjects: 20
Study 34655331 — intervention group
Group type: EXPERIMENTAL
Intervention: Static graded upper-body exercise in cold (-15°C)
Number of subjects: 20
Study 34655331 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy dynamic exercise
Number of subjects: 20
Study 34655331 — intervention group
Group type: COMPARATOR
Intervention: Dynamic graded upper-body exercise in neutral (+22°C)
Number of subjects: 20
Study 34655331 — intervention group
Group type: COMPARATOR
Intervention: Static graded upper-body exercise in neutral (+22°C)
Number of subjects: 20
Study 34655377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bhattacharjee pupil expansion ring
Number of subjects: 25
Study 34655377 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during surgery
Number of subjects: 25
Study 34655570 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG solution
Number of subjects: 37
Study 34655570 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG solution with casein addition
Number of subjects: 37
Study 34655570 — intervention group
Group type: COMPARATOR
Intervention: Control (water) exposure
Number of subjects: 37
Study 34655683 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography scans every 6 months over 2 years
Number of subjects: 250
Study 34655683 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AAA volume, tortuosity, MTD, current tobacco use, angiotensin II receptor blocker use, and history of diabetes mellitus
Number of subjects: 250
Study 34655838 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus abiraterone acetate and prednisone (AAD arm)
Number of subjects: 128
Study 34655838 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide (APA arm)
Number of subjects: 128
Study 34655838 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus abiraterone acetate and prednisone (APA plus AAP arm)
Number of subjects: 128
Study 34655839 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet therapy with pembrolizumab (PEM) 200 mg every three weeks, encorafenib (ENC) 450 mg once daily, and binimetinib (BIN) 45 mg twice daily
Number of subjects: 15
Study 34655839 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet therapy with PEM, ENC, and BIN
Number of subjects: 15
Study 34655863 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised overfeeding for 8 weeks
Number of subjects: 25
Study 34656090 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational intervention providing consultation and technical assistance on safety and ergonomics, work intensity, and job enrichment over 13 months.
Number of subjects: 0
Study 34656103 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape-sensing robotic-assisted bronchoscopy (SSRAB, Ion™ Endoluminal System)
Number of subjects: 60
Study 34656119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 120
Study 34656119 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 120
Study 34656119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ticagrelor and Clopidogrel)
Number of subjects: 120
Study 34656119 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor vs Clopidogrel
Number of subjects: 120
Study 34656148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction (DR) of IL-17 and IL-23 inhibitors, with dosing intervals prolonged stepwise to achieve 66% and 50% of the original dose.
Number of subjects: 244
Study 34656148 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 244
Study 34656173 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based occupational therapy intervention 'Strategies for Empowering activities in Everyday life' (SEE, version 1.0)
Number of subjects: 0
Study 34656469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin-binding radiotracer using PET/CMR
Number of subjects: 0
Study 34656469 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 0
Study 34656551 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive method that improved sex life 'a lot' at 1 month
Number of subjects: 1879
Study 34656551 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive method that improved sex life 'a little' at 1 month
Number of subjects: 1879
Study 34656551 — intervention group
Group type: EXPERIMENTAL
Intervention: Less or no vaginal bleeding
Number of subjects: 1879
Study 34656551 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening of physical side effects
Number of subjects: 1879
Study 34657151 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PTCy)
Number of subjects: 145
Study 34657341 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Acute Stroke Services (COMPASS) intervention
Number of subjects: 0
Study 34657341 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 34657357 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA mutations present
Number of subjects: 298
Study 34657357 — intervention group
Group type: COMPARATOR
Intervention: BRCA mutations absent
Number of subjects: 298
Study 34657389 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/d during the Maintenance Period
Number of subjects: 73
Study 34657389 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/d during the Titration Period
Number of subjects: 73
Study 34657389 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety outcomes
Number of subjects: 73
Study 34657733 — intervention group
Group type: EXPERIMENTAL
Intervention: BICAMS (Brief International Cognitive Assessment in MS)
Number of subjects: 96
Study 34657825 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app with live health coaching
Number of subjects: 118
Study 34657825 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 118
Study 34658014 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine plus standard care
Number of subjects: 11525
Study 34658014 — intervention group
Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 11525
Study 34659081 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasinezumab, dosage and duration not available
Number of subjects: 0
Study 34659081 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 34659107 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34659208 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocetra™-OTS (early apoptotic cell) infusion
Number of subjects: 10
Study 34659886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab monotherapy (2/3 L cohorts)
Number of subjects: 207
Study 34659886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy (1 L cohorts)
Number of subjects: 207
Study 34659886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (2/3 L cohorts)
Number of subjects: 207
Study 34659886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab alone or combined with chemotherapy
Number of subjects: 207
Study 34659886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 207
Study 34660302 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NCT) including adriamycin plus cyclophosphamide followed by intravenous docetaxel for 24 weeks
Number of subjects: 187
Study 34660302 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant Endocrine Therapy (NET) involving goserelin acetate and daily tamoxifen for 24 weeks
Number of subjects: 187
Study 34660457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 132
Study 34660457 — intervention group
Group type: COMPARATOR
Intervention: Lactose granules (placebo)
Number of subjects: 132
Study 34660617 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-operative transcutaneous electrical stimulation
Number of subjects: 0
Study 34660617 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34660654 — intervention group
Group type: EXPERIMENTAL
Intervention: KOKO Plus (macronutrient- and micronutrient-fortified complementary food supplement)
Number of subjects: 0
Study 34660654 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 34660661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild malnutrition
Number of subjects: 4863
Study 34660712 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid
Number of subjects: 0
Study 34660712 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard care)
Number of subjects: 0
Study 34660853 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab treatment
Number of subjects: 1
Study 34661177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy
Number of subjects: 125
Study 34661177 — intervention group
Group type: COMPARATOR
Intervention: Placebo-chemotherapy
Number of subjects: 125
Study 34661873 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe grey matter abnormalities
Number of subjects: 114
Study 34661873 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe ventricular dilatation abnormalities
Number of subjects: 114